This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
/ / /
/ / /

For healthcare professionals only

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.

 

This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.

 

This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.

I hereby declare I am a non-US health care professional and that I have read and agreed to the terms mentioned above.

Scroll down

Diabetes →

 

Obesity →

 

5K run/walk →

RYBELSUS® – The only type 2 diabetes pill

 

RYBELSUS® (semaglutide tablets) is the only GLP-1 RA in a pill, which can deliver HbA1c reduction with the added benefit of weight loss, helping your patients to reduce the risk of long-term complications associated with type 2 diabetes.1-4

Digital Health solutions

As an increasing number of people worldwide are living with diabetes, our device and digital therapeutic innovations have the potential to support diabetes management.

An early SHIFT in treatment could change lives

 

When it comes to treating type 2 diabetes, there are more options available than ever before. But a SHIFT in treatment towards early and intensive HbA1c control can reduce the risks associated with type 2 diabetes and help your patients avoid long term complications.5-7

ASCVD in type 2 diabetes

 

Atherosclerosis is the predominant cause of CVD and death in people with type 2 diabetes.

Rethink Obesity

Connecting medical professionals to the tools they need to manage obesity effectively.
NN 100 Driving change

A century of breakthroughs in health has shown us that progress is only made possible by driving change. As Novo Nordisk turns 100, we renew our commitment to drive change for a healthy world today, and for generations to come.

We invite you to explore our heritage and the legacy of our founders which have characterised our past and will define our future.

1.

RYBELSUS® [summary of product characteristics]. Bagsværd, Denmark: Novo Nordisk A/S; April 2023.

2.

Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. 2019 Apr 16;321(15):1466-1480.

3.

Rodbard HW, Rosenstock J, Canani LH, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care. 2019 Dec;42(12):2272-2281.

4.

Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019;394(10192):39-50.

5.

Dalsgaard N, Vilsbøll T, Knop FK. Effects of glucagon-like peptide receptor agonists on cardiovascular risk factors: A Narrative review of head-to-head comparisons. Diabetes Obes Metab. 2018;20;508-19.

6.

Nauck MA, Quast DR, Wefers J. et al. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab. 2021;46:101-102.

7.

Lovshin JA. Glucagon-like Peptide-1 Receptor Agonists: A class update for treating Type 2 Diabetes. Can J Diabetes. 2017;41:523-35.

5.

Dalsgaard N, Vilsbøll T, Knop FK. Effects of glucagon-like peptide receptor agonists on cardiovascular risk factors: A Narrative review of head-to-head comparisons. Diabetes Obes Metab. 2018;20;508-19.

6.

Nauck MA, Quast DR, Wefers J. et al. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab. 2021;46:101-102.

7.

Lovshin JA. Glucagon-like Peptide-1 Receptor Agonists: A class update for treating Type 2 Diabetes. Can J Diabetes. 2017;41:523-35.

FOR HEALTHCARE PROFESSIONALS ONLY

 

The information contained in this site is intended for healthcare professionals only outside of the United States of America. This site is not intended to provide medical advice and/or treatment guidance. Only a physician can determine whether a specific product is correct for a particular patient. This site is not country-specific and therefore may contain information which is not applicable to your country. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional. Any images shown on the page are a mix of models and real patients.

 

HQ23NNG00014, October 2023